Nolan Townsend, Lexeo Therapeutics CEO
July 15, 2024 07:41 AM EDTUpdated July 16, 12:46 PM
R&D
Cell/Gene Tx

Up­dat­ed: Lex­eo Ther­a­peu­tic­s' gene ther­a­py shows po­ten­tial for Friedre­ich's atax­ia car­diomy­opa­thy with ear­ly da­ta

Katherine Lewin

News Reporter

Lex­eo Ther­a­peu­tics thinks its gene ther­a­py has the po­ten­tial for ac­cel­er­at­ed ap­proval fol­low­ing pos­i­tive in­ter­im da­ta from two ear­ly-stage stud­ies,

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times